ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2097

Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis
Abstract Number: 2098

Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
Abstract Number: 2099

Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Abstract Number: 2100

Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus
Abstract Number: 2101

Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Abstract Number: 2102

Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
Abstract Number: 2103

Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus
Abstract Number: 2104

The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Abstract Number: 2105

Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 2106

Disparities of African American Mortality Trends in South Carolina Lupus Cohort
Abstract Number: 2107

Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
Abstract Number: 2108

Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Abstract Number: 2109

Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 2110

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Abstract Number: 2111

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].